129 related articles for article (PubMed ID: 9466358)
41. 99mTc direct labeling of anti-CEA monoclonal antibodies: quality control and preclinical studies.
De Castiglia SG; Duran A; Fiszman G; Horenstein AL
Nucl Med Biol; 1995 Apr; 22(3):367-72. PubMed ID: 7627152
[TBL] [Abstract][Full Text] [Related]
42. Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging.
Mandikian D; Rafidi H; Adhikari P; Venkatraman P; Nazarova L; Fung G; Figueroa I; Ferl GZ; Ulufatu S; Ho J; McCaughey C; Lau J; Yu SF; Prabhu S; Sadowsky J; Boswell CA
MAbs; 2018; 10(8):1269-1280. PubMed ID: 30199303
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and evaluation of 99mTc-labelled monoclonal antibody 1D09C3 for molecular imaging of major histocompatibility complex class II protein expression.
Malviya G; de Vries EF; Dierckx RA; Signore A
Mol Imaging Biol; 2011 Oct; 13(5):930-9. PubMed ID: 20812032
[TBL] [Abstract][Full Text] [Related]
44. Factors affecting chemistry of reduction-mediated 99mTc-labelling of monoclonal antibodies and polyclonal human immunoglobulins.
Boonkitticharoen V; Puchinda D; Ayudhya AN; Kraiphibul P
J Med Assoc Thai; 2001 Apr; 84(4):545-53. PubMed ID: 11460967
[TBL] [Abstract][Full Text] [Related]
45. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
46. Investigations of directly labeling antibodies with rhenium-188.
Winnard P; Virzi E; Fogarasi M; Rusckowski M; Hnatowich DJ
Q J Nucl Med; 1996 Jun; 40(2):151-60. PubMed ID: 8909100
[TBL] [Abstract][Full Text] [Related]
47. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
[TBL] [Abstract][Full Text] [Related]
48. Investigation of novel bis- and tris-tetraazamacrocycles for use in the copper-64 ((64)Cu) radiolabeling of antibodies with potential to increase the therapeutic index for drug targeting.
Ramli M; Smith SV; Lindoy LF
Bioconjug Chem; 2009 May; 20(5):868-76. PubMed ID: 19397314
[TBL] [Abstract][Full Text] [Related]
49. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
[TBL] [Abstract][Full Text] [Related]
50. Labeling of epirubicin with technetium-99m: Optimization, biodistribution and scintigraphic imaging in tumor bearing mice.
Hina S; Bokhari TH; Roohi S; Rajoka MI; Sohaib M
Pak J Pharm Sci; 2018 Mar; 31(2):517-524. PubMed ID: 29618443
[TBL] [Abstract][Full Text] [Related]
51. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
[TBL] [Abstract][Full Text] [Related]
52. Biodistribution of (125)I-labeled anti-endoglin antibody using SPECT/CT imaging: Impact of in vivo deiodination on tumor accumulation in mice.
Karmani L; Levêque P; Bouzin C; Bol A; Dieu M; Walrand S; Vander Borght T; Feron O; Grégoire V; Bonifazi D; Michiels C; Lucas S; Gallez B
Nucl Med Biol; 2016 Jul; 43(7):415-23. PubMed ID: 27179250
[TBL] [Abstract][Full Text] [Related]
53. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody.
Goldenberg A; Masui H; Divgi C; Kamrath H; Pentlow K; Mendelsohn J
J Natl Cancer Inst; 1989 Nov; 81(21):1616-25. PubMed ID: 2795690
[TBL] [Abstract][Full Text] [Related]
54. Labelling of the anti-III-neurotubulin monoclonal antibody by 99mTc and its binding to responsible antigen.
Slapnicková K; Kolárová P; Kynclová K
Nucl Med Rev Cent East Eur; 2007; 10(1):1-5. PubMed ID: 17694493
[TBL] [Abstract][Full Text] [Related]
55. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
56. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
57. Radioimmuno targetting (99m)technetium labeled anti-epidermal growth factor receptor monoclonal antibodies in experimental tumor models.
Meenakshi A; Ganesh V; Suresh Kumar R; Siva Kumar N
Q J Nucl Med; 2003 Jun; 47(2):139-44. PubMed ID: 12865874
[TBL] [Abstract][Full Text] [Related]
58. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
[TBL] [Abstract][Full Text] [Related]
59. Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice.
Meijs WE; Haisma HJ; Klok RP; van Gog FB; Kievit E; Pinedo HM; Herscheid JD
J Nucl Med; 1997 Jan; 38(1):112-8. PubMed ID: 8998164
[TBL] [Abstract][Full Text] [Related]
60. A new method of technetium-99m labeling of monoclonal antibodies through sugar residues. A study with TAG-72 specific CC-49 antibody.
Ranadive GN; Rosenzweig HS; Epperly MW; Seskey T; Bloomer WD
Nucl Med Biol; 1993 Aug; 20(6):719-26. PubMed ID: 8401372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
